From Evidence to Impact: How Thelansis Accelerated a Rare Disease Submission
Introduction: In recent years, the healthcare landscape has evolved toward an evidence-based, patient-centric architecture. Although conventional clinical trials remain the gold standard, they do not always capture the full gamut of patient experience, follow-up behavior, and the long-term impact of standard-of-care practices observed in real-world settings. To bridge this gap, our team leveraged Real-World Evidence (RWE) analytics and transformed patient data into regulatory-grade insights to support faster approvals and lifecycle management of therapies. Client Overview: A mid-sized biopharmaceutical company developing an orphan drug for a rare metabolic disorder approached Thelansis to strengthen its regulatory submission with RWE. While the client’s Phase III trial demonstrated efficacy in controlled settings, regulators requested additional post-market and real-world validation to understand long-term safety and treatment effectiveness across a broader population. The cl...